[NavBar.htm]

Senior Journal: Today's News and Information for Senior Citizens & Baby Boomers

More Senior Citizen News and Information Than Any Other Source - SeniorJournal.com

Go to more on Health & Medicine or More Senior News from SeniorJournal.com on the Front Page

   
Follow on  and 

E-mail this page to a friend!

Health & Medicine for Senior Citizens

Patients Unable to Lower Bad Cholesterol with Statins Find Success with New Drug

AMG 145 reduced LDL cholesterol by 66% in only 12 weeks

Nov. 6, 2012 - People taking statin drugs to lower "bad cholesterol" levels sometimes are unsuccessful due to their body's inability to tolerate or sufficiently respond to the medicine. Researchers announced today, however, that with the addition of a new drug - AMG 145 - they were able to help these patients reduce the LDL cholesterol by 66 percent in only 12 weeks.

The study by researchers at Brigham and Women's Hospital was presented at the 2012 American Heart Association Scientific Sessions and electronically published in Lancet today.

"The observed reductions in LDL cholesterol are extraordinary, especially when one considers that they are seen on top of statin therapy," said Robert Giugliano, MD, BWH Cardiovascular Division, Department of Medicine, investigator for the Thrombolysis in Myocardial Infarction (TIMI) Study Group, and lead study author.

 

Related Archive Stories

 
 

Genetically Engineered Tomatoes Do the Work of Good Cholesterol to Reduce Plaque

Mice that ate the freeze-dried, ground tomatoes had less inflammation and reduced plaque build-up in their arteries

Nov. 5, 2012

Bad Cholesterol, Total Cholesterol Reduced by New Probiotic Due Out Next Year

Microorganisms reduced fatty acids tied to dangerous plaque buildup in arteries in study with 127 adults

Nov. 5, 2012


 
 

Read the latest news
> Health & Medicine
>
Today's Headlines

 

In a double-blind, dose-ranging, placebo-controlled study, 631 patients ages 18 to 80 years old with high cholesterol on a stable statin dose (with or without ezetimibe) were randomized to receive one of six different AMG 145 dose regimens or matching placebo. The treatments were given subcutaneously (an injection under the skin) every two or every four weeks for a total of twelve weeks.

In participants who received AMG 145 every two weeks, the drug reduced LDL cholesterol in a dose-dependent manner by 42 to 66 percent at the end of twelve weeks compared to placebo.

For those taking AMG 145 every four weeks, the drug reduced LDL cholesterol in a dose-dependent manner by 42 to 50 percent at the end of twelve weeks compared to placebo. Moreover, just one week after a dose, researchers saw LDL cholesterol reduced by up to 85 percent.

The highest dose given every two weeks also allowed 93.5 percent of patients to achieve the most stringent cholesterol-lowering goals. Furthermore, the researchers noted that there were no serious adverse events that occurred with AMG 145 treatment.

"These data are very exciting and may offer a new paradigm for LDL cholesterol reduction. The next step will be a large-scale, long-term cardiovascular outcomes trial," said Marc Sabatine, MD, chairman of the TIMI Study Group, and senior study author.

AMG 145 is a monoclonal antibody. It binds to a protein that normally shepherds LDL cholesterol receptors for destruction. By blocking that protein, AMG 145 protects the receptors from being destroyed, thereby increasing the number of LDL cholesterol receptors on the surface of the liver that help remove bad cholesterol from the bloodstream.

This research was supported by Amgen, Inc., who participated in the study design and data collection. Data analyses were performed and interpreted independently by the TIMI Study Group, Brigham and Women's Hospital.

 

> Medical Malpractice,

> Nursing Home Abuse,

> Personal Injury

Our Experienced Lawyers Can Help

Beth Janicek, Board Certified Personal Injury Attorney"We win because we care, we prepare and we have no fear," Beth Janicek, board certified personal injury attorney

 

Free Consultation on your case.

Call Now Toll Free

1-877-795-3425

or Send Email

More at our Website

 

 

Search for more about this topic on SeniorJournal.com

Google Web SeniorJournal.com

Keep up with the latest news for senior citizens, baby boomers

 

Click to More Senior News on the Front Page

Copyright: SeniorJournal.com

    

 

Published by New Tech Media - www.NewTechMedia.com

Other New Tech Media sites include CaroleSutherland.com, BethJanicek.com, SASeniors.com, DrugDanger.com, etc.